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Background:  Hepatitis  B virus  (HBV)  and  tuberculosis  (TB)  represent  major  public  health  problems.  There
is currently  little  data  on  HBV  infection  among  TB  patients  with  and  without  human  immunodeﬁciency
virus  (HIV).
Objectives:  To  assess  HBV  prevalence  among  TB  patients  with  and  without  HIV.
Study  design:  From  April  2008  to  March  2010,  a cross-sectional  study  was  conduct  among  TB  patients
attended  at  a reference  hospital  in Goiânia  City,  Brazil.  The  participants  were  tested  for serological  mark-
ers of HBV  infection  and  HIV  antibodies.  HBV  DNA  was  detected  in HBsAg-positive  samples,  and  also  in
HBsAg-negative/anti-HBc-positive  samples  to  look  for HBV  occult  infection.
Results: Of  425  patients,  402 (94.6%)  agreed  to  participate  in the  study.  The  overall  prevalence  of  HBV
(HBsAg  and/or  anti-HBc  positive)  and  HIV  infections  were  25.6%  (103/402)  and  27.6%  (111/402),  respec-
tively.  A  higher  HBV  infection  rate  was found  among  HIV-infected  patients  (36.9%;  41/111)  compared  to
patients  infected  with  TB  only  (20.0%;  57/285).  A multivariate  analysis  of  risk  factors  showed  that  age
≥50  years  (p = 0.03),  non-injecting  (p <  0.01)  and  injecting  (p  < 0.01)  drugs  use  were  associated  with  HBV
infection.  Among  the  HBsAg-positive  samples  (n = 13),  HBV  DNA was  detected  in 10  (76.9%)  samples.  Of
the 90  anti-HBc-positive  samples,  13 were  HBV  DNA  positive  (with  very  low  levels)  resulting  in  an  occult
HBV  infection  rate  of  14.4%.  PCR-RFLP  was  successfully  performed  in  20 HBV  DNA-positive  samples:  15
were genotype  A  and  5 were  genotype  D.
Conclusions:  HBV  infection  was  common,  particularly  among  this  with  HIV infection.. Background
Hepatitis B virus (HBV) remains a major cause of liver disease
orldwide despite vaccination programs implemented over the
ast decade. Worldwide, it is estimated that 2 billion people are
nfected with HBV and that more than 350 million are chronically
nfected. Patients with chronic hepatitis B are at risk for developing
iver cirrhosis and hepatocellular carcinoma.1 In high prevalence
reas, most HBV infection is acquired during the perinatal period
r early in childhood. In contrast, in intermediate to low endemic
reas, this infection occurs mainly in young adults and is dissemi-
ated either by parenteral or sexual transmission.2
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HBV infection is diagnosed commonly by the presence of hep-
atitis B surface antigen (HBsAg), which is indicative of acute or
chronic infection. HBV DNA has, however, been detected in the
liver and/or blood of individuals without detectable HBsAg. This
condition is called occult HBV infection and its prevalence varies
signiﬁcantly between geographic regions as well as between pop-
ulations. In terms of public health, the clinical importance of occult
HBV infection arises from the risk of HBV transmission despite the
low levels of HBV DNA.3,4 Based on an intergroup divergence of
complete nucleotide sequences of 7.5% or greater, HBV has been
classiﬁed into eight genotypes (A–H), which have a characteristic
geographic distribution.5
Tuberculosis (TB) is still among the most life-threatening infec-
tious diseases, resulting in high mortality rates in adults. According
Open access under the Elsevier OA license.to the World Health Organization, the estimate of the global burden
of TB in 2010 was 8.8 million incident cases (range, 8.5–9.2 million)
and 12 million prevalent cases (range, 11–14 million).6 In Brazil,
approximately 63 million people are infected with the TB bacilli
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acteristics of the study population are shown in Table 1. The mean
age was 44.1 years (standard deviation = 15.6). Most patients were
males (71.9%). Almost half of the study group (42.3%) was  single,
and 65.9% were non-Caucasian (most of them were Afro-Brazilian).
Table 1
Sociodemographic characteristics of 402 patients with tuberculosis in Goiânia City,
Brazil.
Characteristics n %
Age (mean ± SD: 44.1 ± 15.6)
<30 years 75 18.7
30–39 years 98 24.4
40–49 years 93 23.1
≥50  years 136 33.8
Gender
Male 289 71.9
Female 113 28.1
Marital status
Single 170 42.3
Married 157 39.0
Divorced/widowed 75 18.7
Race/ethnicity
Caucasian 137 34.1
Non-caucasian 265 65.9
Schoolinga
<5 years 127 31.8
5–9  years 192 48.0
10–12 years 65 16.2
>12  years 16 4.0
Monthly incomeb
≤1 minimum salary 247 63.8
>1  minimum salary 121 31.328 R.S. Aires et al. / Journal of Cl
ith approximately 71,000 new cases reported every year, result-
ng in 4600 yearly deaths.7 Human immunodeﬁciency virus (HIV) is
he most signiﬁcant risk factor associated with acquiring TB disease
n those with latent or newly acquired Mycobacterium tuberculo-
is infections.6 Moreover, HIV and/or HBV co-infections increase
he risk of anti-TB drug-induced hepatotoxicity, which may  neces-
itate discontinuation of treatment.8–11 Since TB and hepatitis B
ay  co-exist in patients from endemic areas, some reports sug-
est to provide HBV testing to TB patients, which may  improve TB
anagement and treatment (through careful monitoring and treat-
ent adjustment when necessary).9,11 Although hepatitis B may
lso impact patients with TB, there is currently very little data on
BV prevalence and risk factors among TB patients8,9,11–14; and no
ata are available regarding hepatitis B occult and HBV genotypes
nfecting these patients.
. Objectives
This study aimed to assess the prevalence of HBV infection
mong TB patients with and without HIV in Goiânia City, Brazil.
ccult hepatitis B, risk factors and HBV genotypes were also inves-
igated.
. Study design
.1. Patients
This is a seroprevalence survey of TB patients for HBV with and
ithout HIV in Goiânia City (estimated population of 1,300,000),
he capital of the Goiás State in Brazil. All patients with clinical
iagnosis of TB at out-patient and in-patient units at the Anuar Auad
ospital (the reference hospital for infectious diseases in Goiânia)
ere invited to participate in the study.
From April 2008 to March 2010, participants were recruited
hrough physicians who explained the study objectives and pro-
edures. After written informed consent was obtained from all
articipants, they were interviewed to collect data on socio-
emographic, risk factors for HBV infection, and HBV vaccination
tatus.
Participants were invited to receive HBV and HIV testing and
ere offered pre-test and post-test counseling. All seropositive
atients were subsequently referred for medical follow-up and
reatment was offered according to Brazilian guidelines.15,16
The protocol used for the present study was approved by the
thical Committee of the Anuar Auad Tropical Disease Hospital,
oiânia, Goiás, Brazil.
.2. Blood samples collection and serological tests
Blood was collected (10 ml)  from all participants and serum
amples were tested by enzyme-linked immunosorbent assay
ELISA) for the presence of HBsAg (Hepanostika HBsAg Ultra,
iomérieux, Boxtel, The Netherlands), antibodies to the total
epatitis B core antigen (anti-HBc) (Hepanostika anti-HBc Uni-
orm, Biomérieux) and hepatitis B surface antibodies (anti-HBs)
Bioelisa anti-HBs, Biokit, Barcelona, Spain). HBsAg-positive sam-
les were assayed for IgM anti-HBc (Bioelisa anti-HBc IgM,
iokit), hepatitis B e antigen (HBeAg) and antibody for HBeAg
anti-HBe) (Eti-Ab/Ebk Plus, Diasorin, Italy). Baseline serum
amples were also tested by ELISA for anti-HIV-1.2.0 (Murex
iotech, Dartford, UK). HIV-positive samples were conﬁrmed
y Western blot (Bio Rad Laboratories, Marnes La Coquette,
rance).Virology 54 (2012) 327– 331
3.3. PCR ampliﬁcation and HBV genotyping
DNA was extracted from HBsAg and anti-HBc-positive
samples.17 The Pre-S/S genome region was ampliﬁed using a
semi-nested PCR assay (detection limit of three copies of HBV DNA
per reaction) and the amplicons genotyped by restriction fragment
length polymorphism (RFLP) analysis.18,19
3.4. Quantiﬁcation of HBV DNA
HBV DNA-positive samples were quantiﬁed using the real-time
PCR TaqMan technology, according to Pas and Niesters with some
modiﬁcations.20,21
3.5. Data analysis
Prevalence and 95% conﬁdence intervals (95% CI) were calcu-
lated. The overall prevalence of HBV infection was  deﬁned by the
presence of HBsAg and/or anti-HBc in serum. Potential risk fac-
tors for current or previous HBV infection (deﬁned as positive for
HBsAg and/or anti-HBc markers) were initially assessed by univari-
ate analysis. Categorical variables were compared using Pearson’s
2 test or Fisher’s exact test. A p value ≤0.10 was  used to select
variables for inclusion in a multivariate logistic regression model.
These variables are listed in Table 3. A p value of <0.05 was deﬁned
as statistically signiﬁcant. Data were analyzed using SPSS, version
11.0 (SPSS Inc., Chicago, US, 1999).
4. Results
A  total of 425 TB patients were invited to take part in the study.
Of these, 402 (94.6%) agreed to participate. Sociodemographic char-SD, standard deviation.
a Two  children age <6 years were excluded (n = 400).
b The information for this variable is not based on the total population size owing
to  incomplete questionnaire information (n = 15). Minimum monthly salary was
approximately equal to US$300.
inical Virology 54 (2012) 327– 331 329
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Table 2
Prevalence of HBV serological markers among patients with tuberculosis with or
without HIV in Goiânia City, Brazil.
HBV markers TB only (n = 285)
No. (%)
TB/HIV (n = 111)
No. (%)
Total (n = 402)a
No. (%)
HBsAg 4 (1.4) 1 (0.9) 5 (1.2)
Anti-HBc 4 (1.4) 3 (2.7) 9 (2.2)
HBsAg/anti-HBc 5 (1.7) 3 (2.7) 8 (2.0)
Anti-HBc/anti-
HBs
44 (15.4) 34 (30.6) 81 (20.1)
Any exposure
marker
57 (20.0) 41 (36.9) 103 (25.6)
Anti-HBs 31 (10.9) 12 (10.8) 44 (10.9)
T
F
OR.S. Aires et al. / Journal of Cl
early 80.0% of the participants had received 9 years or less of
ormal education (fundamental education in Brazil) and 63.8%
eported an income of US$300 or less.
As shown in Table 2, 103 of the 402 patients (25.6%) had serolog-
cal markers of current or previous HBV infection. Of these, 13 (3.2%)
ere HBsAg-positive, 9 were reactive for total anti-HBc only and
1 were anti-HBs and total anti-HBc-positive. In addition, 10.9%
44/402) of the study population were reactive for isolated anti-
Bs. One hundred and eleven patients (27.6%) were HIV-positive,
85 were HIV-negative and 6 had an undetermined HIV infection
tatus. The overall prevalence of HBV infection among HIV-infected
atients (36.9%; 41/111) was higher than in patients infected with
B only (20.0%; 57/285; 2 = 12.3, p < 0.01). However, HBsAg rates
ere similar in both groups (3.6% versus 3.1%; p > 0.05).
able  3
actors associated with hepatitis B virus (HBV) among patients with tuberculosis in Goiân
Risk factor HBV Pos./totala (%) OR (95%
Age (n = 358)
<30 years 14/58 (24.1) 1.0 
30–39 years 23/91 (25.3) 1.1 (0.5
40–49  years 25/86 (29.1) 1.3 (0.6
≥50  years 41/123 (33.3) 1.6 (0.7
Gender (n = 358)
Female 20/96 (20.8) 1.0 
Male  83/262 (31.7) 1.8 (1.0
History of familial hepatitis (n = 330)
No 74/279 (26.5) 1.0
Yes 18/51 (35.3) 1.5 (0.8
Previous blood transfusion (n = 357)
No 63/243 (25.9) 1.0 
Yes 40/114 (35.1) 1.5 (1.0
Previous surgery (n = 356)
No 47/172 (27.3) 1.0
Yes  56/184 (30.4) 0.9 (0.5
History of tattoos/piercings (n = 357)
No 76/283 (26.9) 1.0 
Yes  27/74 (36.5) 1.6 (0.9
History of acupuncture (n = 351)
No 99/344 (28.8) 1.0
Yes 3/7 (42.9) 1.8 (0.4
History of sharing cutting instruments (n = 353)
No 66/237 (27.8) 1.0
Yes  35/116 (30.2) 1.1 (0.7
History of hemodialysis (n = 356)
No 99/352 (28.1) 1.0 
Yes  3/4 (75.0) 7.7 (0.8
Ever  used illicit drugs (n = 358)
No 68/265 (25.7) 1.0 
Non-injecting 25/72 (34.7) 1.5 (0.9
Injecting 10/21 (47.6) 2.6 (1.0
Ever  incarceration (n = 358)
No 72/267 (27.0) 1.0
Yes  31/91 (34.1) 1.4 (0.8
Lifetime number of sexual partners (n = 347)
≤2 13/57 (22.8) 1.0 
3–5  12/65 (18.5) 0.8 (0.3
>5  77/225 (34.2) 1.8 (0.9
Ever  male homosexual contact (n = 262)
No 70/232 (30.2) 1.0
Yes  13/30 (43.3) 1.8 (0.8
Condom use during last intercourse (n = 337)
Yes 63/228 (27.6) 1.0
No  35/109 (32.1) 1.2 (0.7
Previous STI (n = 338)
No 54/206 (26.2) 1.0
Yes  41/132 (31.1) 1.3 (0.8
Ever  alcohol consumption (n = 358)
No 27/126 (21.4) 1.0 
Yes  76/232 (32.8) 1.8 (1.1
R, odds ratio; CI, conﬁdence interval; STI, sexually transmitted infections.
a HBV vaccinated individuals were excluded.
b Adjusted for age, gender, blood transfusion, tattoo/piercings, hemodialysis, drug use, a Anti-HIV undetermined: 2 anti-HBc, 3 anti-HBc/anti-HBs and 1 anti-HBs only.
ia City, Brazil.
 CI) p value Adjusted OR (95% CI)b p value
1.0
–2.4) 0.87 0.9 (0.4–2.1) 0.90
–3.0) 0.51 1.7 (0.7–4.0) 0.22
–3.4) 0.21 2.6 (1.1–6.3) 0.03
1.0
–3.1) 0.04 1.3 (0.6–2.6) 0.47
–2.8) 0.20 –
1.0
–2.5) 0.07 1.5 (0.9–2.5) 0.10
–1.4) 0.51 –
1.0
–2.7) 0.10 1.4 (0.7–3.0) 0.37
–8.4) 0.42 –
–1.8) 0.65 –
1.0
–74.6) 0.07 4.3 (0.4–46.1) 0.22
1.0
–2.8) 0.12 2.7 (1.3–5.6) <0.01
–7.0) 0.03 3.7 (1.4–10.0) <0.01
–2.3) 0.20 –
1.0
–2.0) 0.55 0.9 (0.4–2.3) 0.84
–3.7) 0.10 1.7 (0.8–3.5) 0.16
–3.8) 0.14 –
–2.0) 0.40 –
–2.0) 0.33 –
1.0
–3.0) 0.02 1.4 (0.8–2.4) 0.26
lifetime number of sexual partners and alcohol consumption.
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Among the HBsAg-positive samples (n = 13), IgM anti-HBc
arker was detected in four serum samples. In addition, the
BeAg and anti-HBe markers were found in two and eight
amples, respectively. HBV DNA was detected in 10 (76.9%) HBsAg-
ositive samples. Of 81 total anti-HBc/anti-HBs reactive samples,
2 (14.8%) were HBV DNA-positive. Among the 9 total anti-
Bc only reactive samples, one (11.1%) was HBV DNA-positive.
hese results were conﬁrmed by repeating both the DNA extrac-
ion and ampliﬁcation procedures, thereby establishing the occult
BV infection rate at 14.4% (13/90) among total anti-HBc-positive
B patients. As expected, HBV DNA levels were signiﬁcantly
ower in patients with occult infection (range: 1.7 × 102 to
.7 × 102 copies/ml, mean: 3.3 × 102 copies/ml) compared to those
ho were HBsAg-positive (range: 6.9 × 103 to 2.4 × 108 copies/ml,
ean: 2.5 × 107 copies/ml). PCR-RFLP was successfully performed
n 20 HBV DNA-positive samples, with isolates belonging to the
BV genotypes A (n = 15) and D (n = 5).
Univariate analysis of risk factors for HBV infection revealed
hat male gender, injecting drug use and alcohol consumption
ere associated with this infection. In a multivariate analysis, age
50 years (p = 0.03), non-injecting (p < 0.01) and injecting (p < 0.01)
rugs use were independent risk factors associated with HBV infec-
ion (Table 3).
. Discussion
The overall prevalence of HBV infection found among TB
atients was higher than those reported in other Brazilian popula-
ions such as individuals reporting to an HIV Testing and Counseling
enter (14.6%; 95% CI: 11.2–18),22 patients attending a Sexually
ransmitted Diseases Clinic (13%; 95% CI: 10.0–16.5) and non-
njecting drug users (14%; 95% CI: 11.7–16.5).23,24 The prevalence
etermined in this study was within the conﬁdence interval range
eported for injecting drug users (27.1%; 95% CI: 23.6–30.8) and
emodialysis patients (29.8%; 95% CI: 27.1–32.5).25,26
Relative to other data reported in TB patients, the HBV preva-
ence determined in this study was similar to prevalence rates
bserved in Rio de Janeiro, Brazil (26.8%; 95% CI: 19.7–31.9) and
rgentina (19.8%; 95% CI: 14.3–26.2),12,13 but was higher than rates
etermined in Georgia (13%; 95% CI: 9.5–17.5) and Taiwan (11.7%;
5% CI: 6.8–15.5).9,11
The high prevalence rates of HBV infection found in TB/HIV-
nfected patients and in patients with TB only were similar to those
bserved in Rio de Janeiro (35.8% and 14.6%, respectively).12 Other
tudies have indicated that HBV and HIV infections have been found
o increase the risk of anti-TB drug-induced hepatotoxicity that
ay  necessitate discontinuation of treatment.8–11 Among the HBV
nfected patients, two developed hepatotoxicity: one patient dur-
ng the ﬁrst month of TB treatment (HBsAg/HBeAg-positive and had
 high HBV DNA level: 6.7 × 106 copies/ml), while the other patient
uring the second month of TB treatment (had occult HBV infec-
ion with HBV DNA level of 1.9 × 102 copies/ml). In both cases, TB
reatment adjustment was necessary (data not shown).
In the present study, age ≥50 years was associated with HBV
nfection, which was consistent with another study characteriz-
ng TB patients in Argentina.13 Age may  be a proxy for lifetime
xposure, indicating that, over time, there is a cumulative risk of
BV infection linked to sexual and percutaneous exposures. In fact,
njecting drug use was an independent risk factor for HBV infection
n the study population described in this report. This behavior has
een reported by others among TB patients,9,13 reﬂecting the high
ransmissibility of HBV through direct blood contact resulting from
he sharing of syringes and needles. In addition, non-injecting drug
se was statistically associated with HBV infection in the study pop-
lation described here, which was probably linked to percutaneousVirology 54 (2012) 327– 331
exposures related to sharing of non-injection drug implements
such as pipes and straws for smoking and snifﬁng/snorting, which
could lead to blood-to-blood contact. These behaviors have been
suggested by others to lead to the HBV exposure by non-injecting
drug users.27
The present study provides the ﬁrst set of data describing the
prevalence of occult HBV infection in TB patients. Although no sim-
ilar reports are available for direct comparison, the proportion of
occult HBV infection among the anti-HBc-positive patients identi-
ﬁed was similar to that reported in HIV infected patients in Brazil
(14%),28 but higher than that observed in Brazilian blood donors
(4%).29
The HBV genotypes A (n = 15) and D (n = 5) identiﬁed in the HBV
DNA-positive TB patients were in accordance with data reported
in other populations in Brazil where genotype A predominated,
followed by genotype D.19,21,24,26,30
Only 44 (10.9%) TB patients were reactive for isolated anti-
HBs, suggesting that they had been vaccinated for HBV. In fact,
all of them self-reported an HBV vaccination (38 had received
three doses and the remaining two doses). In Brazil, the National
Immunization Program recommends administration of the hepati-
tis B vaccine for newborns, children and young adults under 24
years of age, as well as for high-risk individuals but not for TB
patients.
TB control remains a great challenge for public health globally.6
Hepatotoxicity development during anti-TB treatment is the most
important adverse event, and could result in low treatment
success.8–11 Although the incidence of hepatotoxicity during TB
treatment is outside the scope of this cross-sectional study, it was
possible to identify two  HBV infected patients who developed
hepatotoxicity during TB treatment. Therefore, further clini-
cal prospective studies with a close follow-up of HBV/TB and
HBV/HIV/TB co-infected patients are necessary and, thus, optimize
the management of these important infections.
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